Ocotillol Type Ginsenoside Derivatives

PreclinicalSmall molecule

Ocotillol Type Ginsenoside Derivatives is one of 33 small molecule programs targeting Acute Lung Injury. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Lung InjuryActive, not recruiting

Acute Lung InjuryPreclinical

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Acute Lung Injury

#DrugCompanyPhaseTrials

Gleevec

Novartis

Approved

—2

Kalydeco

Vertex Pharmaceuticals

Approved

—3

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

1 4

Pitressin

AAultman Health Foundation

Approved

—5

Neo-Synephrine

EExela Pharma Sciences, LLC.

Approved

—6

Oxbryta

GGlobal Blood Therapeutics

Approved

—7

Esbriet

LLegacy Health System

Approved

—8

Adrenaline

SSamson Clinical Operations Pty Ltd

Ultomiris

Heparin Sodium

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Lung Injury1 trial

Mechanism of Delayed Neutrophil Apoptosis in Acute Lung Injury

Completed·TThe First Hospital of Jilin University··NCT04607434·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ocotillol Type Ginsenoside Derivatives. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ocotillol Type Ginsenoside Derivatives compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ocotillol Type Ginsenoside Derivatives. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Hospital of Jilin University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe First Hospital of Jilin University

Ocotillol Type Ginsenoside Derivatives

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Lung Injury1 trial

References

Drug Info

Quick Facts

Related News